From Earlier: Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID for the Treatment of Alzheimer's Disease

Baxter International Inc. (NYSE: BAX) yesterday provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] (marketed as KIOVIG outside the United States and Canada), for the treatment of mild to moderate Alzheimer's disease. The company plans to initiate a second, confirmatory Phase III trial in the first quarter of 2012, having satisfactorily completed a futility analysis in its first Phase III trial.